Technavio Announces the Publication of its Research Report – Global Automation Market in Biopharmaceutical Industry 2017-2021

Technavio recognizes the following companies as the key players in the global automation market in biopharmaceutical industry: Danaher, GE, PerkinElmer, Tecan Trading, and Thermo Fisher Scientific.

Other Prominent Vendors in the market are: Bruker, Peak Analysis & Automation, Waters, Capsugel, RheoSense, Eirechrom, BioProcess International, and Novasep.

View Our Report @ https://marketreportscenter.com/reports/556703/global-automation-market-in-biopharmaceutical-industry-2017-2021

Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is continuous manufacturing. Advantages of continuous operations are well-recognized in various industries. It completes the process in a shorter time as it omits the hold steps, reduces shut down time, and reduces the labor requirement. Over the decades, upstream processing utilized this technology.”

PDF sample download @ https://marketreportscenter.com/reports/556703/global-automation-market-in-biopharmaceutical-industry-2017-2021#

According to the report, one driver in the market is use of automation in data acquisition. Traditionally, research labs collect data manually and store it in spreadsheets. This method is not only time-consuming but also affects operational efficiency and is prone to errors. It also restricts monitoring of data in real time. The biopharmaceutical industry is working on data collection and adding the information from spreadsheets to a database. Database collection of upstream and downstream processes is being utilized to create a library that increases operational efficiency and process optimization.

Buy Discounted Copy @ https://marketreportscenter.com/request-discount/556703

Further, the report states that one challenge in the market is high R&D cost. The biopharmaceutical industry is a rapidly growing industry in pharmaceuticals. Complex drugs are manufactured with the help of 3-D modeling and are produced with high efficacy and precision. These drugs can provide medication to medical issues that were once incurable. Currently, the biopharmaceutical industry is looking to yield new products to address diseases such as cancer, Alzheimer's disease, and hepatitis C. Innovations in the biopharmaceutical industry are highly expensive. The average cost associated with a new drug is around $2 billion, including the cost of unsuccessful drug approvals, out of which almost $400 million is the cost included in pre-clinical and clinical testing.

Buy Copy Now @ https://marketreportscenter.com/buy-now?sku=TCSEPT172231

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors."